Alto Neuroscience
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Alto Neuroscience sits in the top decile of US sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count).
Alto Neuroscience: 10 sponsored US clinical trials, 4 recruiting.
Alto Neuroscience sponsors 10 registered US clinical trials on ClinicalTrials.gov, 4 of them currently recruiting, and 6 completed. 0 of these trials are in Phase 3-4 (later-stage) and 10 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Major Depressive Disorder, with 5 trials.
Top-decile sponsor footprint
Alto Neuroscience ranks in the top decile of sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
10 total, page 1 of 1
ALTO-207 in Adults With Treatment-resistant Depression (TRD)
NCT07553637
ALTO-100 in Bipolar Disorder With Depression (BD-D)
NCT06656416
Study of ALTO-101 in Patients With Schizophrenia
NCT06502964
Study of ALTO-300 in MDD
NCT05922878
PD, PK, and Safety of ALTO-203 in Patients With MDD
NCT06391593
Phase 2b Study of ALTO-100 in MDD
NCT05712187
Pilot Decentralized Trial
NCT05419869
ALTO-300 in Depression (ALTO-300-004)
NCT05157945
ALTO-100 in MDD and/or PTSD
NCT05117632
ALTO-300 in Depression
NCT05118750
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 10 |
What is open in the Alto Neuroscience pipeline
4 recruiting of 10 indexed (40% open); 6 completed (60%).
Phase mix: 0 late (III/IV) vs 10 early (I/II) (early-phase heavy).
Top condition: Major Depressive Disorder (5 trials), 4 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Alto Neuroscience: open-pipeline peers nationwide
Peers matched on 10 registered trials and 40% open enrollment, not the therapeutic-area sidebar.
Alto Neuroscience sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 10 trials (± recruiting share)
- Adamas Pharmaceuticals · 10 trials · 0% recruiting
- Adverum Biotechnologies · 10 trials · 30% recruiting
- Aevi Genomic Medicine, LLC, a Cerecor company · 10 trials · 0% recruiting
- Agouron Pharmaceuticals · 10 trials · 0% recruiting
Sponsors near 40% open enrollment (± trial volume)
- Ad scientiam · 40% recruiting · 5 trials
- Bonafide Health · 40% recruiting · 5 trials
- Brooks Rehabilitation · 40% recruiting · 5 trials
- C4 Therapeutics · 40% recruiting · 5 trials
Related
What to do with this Alto Neuroscience page
10 registered trials is a research-attention snapshot, not an endorsement of Alto Neuroscience or any single study.
- 4 of Alto Neuroscience's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Major Depressive Disorder is the condition Alto Neuroscience studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Major Depressive Disorder trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Alto Neuroscience pipeline card: 10 registered trials from official public datasets.Report a data error.